Cite
HARVARD Citation
Tournigand, C. et al. (2015). Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. Lancet oncology. 16 (15), pp. 1493-1505. [Online].